收到国家药品监督管理局（以下简称“国家药监局”）核准签发的《药物临床试验批准通知书》，同意AST2303片在EGFR突变的晚期非小细胞肺癌成人患者中开展临床试验。
View details >
News
Talent recruitment mailbox：hr@inveedwin.com
Business cooperation mailbox：--
Headquarters：Room 1011, Building 1, XXX Plaza, XXX Road, XXX District, Shanghai
official account
Copyright 2023 Yiding Wenying Technology (Shanghai) Co., Ltd. 沪ICP备2025115596号-1
